drugset / Trial / NCT01548157

Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule

NCT01548157

Phase 1 Completed 28 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate pharmacokinetics and safety after oral administration of HCP1007 capsules and Rosuvastatin plus Omega-3.

Timeline

Start
2012-03
Primary completion
2012-03
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1007 Unknown Oral
Subject Omega-3 fatty acids Unknown 1 g Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

No indication recorded.